• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib.

作者信息

Molica Matteo, Breccia Massimo, Colafigli Gioia, Massaro Fulvio, Quattrocchi Luisa, Mancini Marco, Diverio Daniela, Latagliata Roberto, Foà Robin

机构信息

Department of Cellular Biotechnologies and Haematology, Sapienza University, Rome, Italy.

出版信息

Br J Haematol. 2018 Apr;181(2):275-278. doi: 10.1111/bjh.14560. Epub 2017 Feb 17.

DOI:10.1111/bjh.14560
PMID:28211562
Abstract
摘要

相似文献

1
Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib.
Br J Haematol. 2018 Apr;181(2):275-278. doi: 10.1111/bjh.14560. Epub 2017 Feb 17.
2
Imatinib resistance due to a novel and rare class of mutation at position S348 (1043nt C→A) of Bcr/Abl gene in a chronic myeloid leukemia patient.一名慢性髓性白血病患者因Bcr/Abl基因第S348位（1043nt C→A）发生一类新型罕见突变导致伊马替尼耐药。
Leuk Res. 2018 Sep;72:96-98. doi: 10.1016/j.leukres.2018.08.008. Epub 2018 Aug 11.
3
Sustained molecular response with nilotinib in imatinib-intolerant chronic myeloid leukaemia with an e19a2 BCR-ABL1 fusion.尼洛替尼治疗不耐受伊马替尼的伴有e19a2 BCR-ABL1融合的慢性髓性白血病的持续分子反应
Hematol Oncol Stem Cell Ther. 2016 Dec;9(4):168-169. doi: 10.1016/j.hemonc.2016.05.007. Epub 2016 Jun 23.
4
Case with chronic myeloid leukemia and T315I mutation, but still in complete molecular response under high dose imatinib therapy.
Leuk Lymphoma. 2014 Jul;55(7):1684-6. doi: 10.3109/10428194.2013.850164. Epub 2013 Nov 14.
5
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.帕纳替尼与伊马替尼用于新诊断的慢性髓性白血病：一项国际、随机、开放标签、3 期临床试验。
Lancet Oncol. 2016 May;17(5):612-21. doi: 10.1016/S1470-2045(16)00080-2. Epub 2016 Apr 12.
6
Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response.慢性髓性白血病患者若未能实现早期分子反应则早期换用二线酪氨酸激酶抑制剂。
Am J Hematol. 2017 Oct;92(10):E602-E604. doi: 10.1002/ajh.24838. Epub 2017 Jul 29.
7
Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent.韩国慢性髓性白血病患者Bcr-Abl激酶结构域突变分析：P环和T315I突变的不良临床结局与疾病分期有关。
Hematol Oncol. 2009 Dec;27(4):190-7. doi: 10.1002/hon.894.
8
The predictive value of early molecular response in chronic myeloid leukaemia patients treated with imatinib in a single real-world medical centre in a developing country.在一个发展中国家的单一真实世界医疗中心接受伊马替尼治疗的慢性髓性白血病患者中，早期分子反应的预测价值。
Singapore Med J. 2017 Mar;58(3):150-154. doi: 10.11622/smedj.2016063. Epub 2016 Mar 31.
9
Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.转换为第二代酪氨酸激酶抑制剂可改善一线接受伊马替尼治疗的慢性髓性白血病患者的反应和预后，这些患者在3个月时BCR-ABL/ABL比值超过10%。
Cancer Med. 2015 Jul;4(7):995-1002. doi: 10.1002/cam4.440. Epub 2015 Mar 10.
10
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.BCR-ABL1 转录本类型影响伊马替尼一线治疗费城染色体阳性慢性髓性白血病患者的反应和结局。
Am J Hematol. 2017 Aug;92(8):797-805. doi: 10.1002/ajh.24774. Epub 2017 May 30.

引用本文的文献

1
Molecular Quantification and Mutation Detection as Essential Tools for the Clinical Management of Chronic Myeloid Leukemia Patients: Results from a Brazilian Single-Center Study.分子定量和突变检测作为慢性髓性白血病患者临床管理的重要工具：来自巴西单中心研究的结果。
Int J Mol Sci. 2023 Jun 14;24(12):10118. doi: 10.3390/ijms241210118.
2
Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib.伊马替尼治疗的慢性髓性白血病患者中与稳定达到MR4.5相关的预后因素。
Oncotarget. 2017 Dec 26;9(7):7534-7540. doi: 10.18632/oncotarget.23691. eCollection 2018 Jan 26.